Global Testicular Cancer Market - 2023-2030

Global Testicular Cancer Market - 2023-2030

Global Testicular Cancer Market reached US$ 811.3 million in 2022 and is expected to reach US$ 1,246.3 million by 2030 growing with a CAGR of 5.6% during the forecast period 2023-2030. The trend such as the shift towards personalized medicine by better understanding of specific genetic makeup is expected to dominate the global testicular cancer market.

The global testicular cancer market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such as the usage of targeted therapies, and emerging immunotherapy options.

Furthermore, the rising prevalence of testicular cancer, advancements in diagnostic technologies, increasing awareness and screening programs, and advancements in treatment options for the disease are driving up the testicular cancer market size. The rising number of clinical trials has resulted in the development of novel treatments is seeing an increase in demand from North American regions with significant competitors like Pfizer Inc., Fresenius Kabi AG, and others actively operating in the market.

Market Dynamics

The Increasing Diagnosis of Testicular Cancer to Drive the Growth of the Testicular Cancer Market

The global testicular cancer market is growing rapidly, owing mainly due an increase in testicular cancer diagnoses worldwide. For instance, according to the American Society of Clinical Oncology (ASCO) report of 2023, testicular cancer will be diagnosed in 9,190 people in the U.S. and 74,458 people globally. Particularly, testicular cancer is the most commonly diagnosed malignancy in men aged 20 to 34, with a growing number of cases observed among men aged between 20 to 29 and 30 to 39.

This trend has increased awareness and screening programs, resulting in earlier detection and improved survival rates. To meet the changing demands of patients, ongoing research and development activities are focused on developing targeted medicines, immunotherapies, and personalized medicine. Thus, owing to the increase in diagnosis of cancer the market is expected to drive over the forecast period.

The Development of Novel Therapeutic Options will Drive the Market Growth

The use of novel therapeutic options is expected to dominate the market. Due to the factors such as resistance developed by conventional therapies such as chemotherapy, and advancements in gene therapies. For instance, in April 2023, researchers at the University Hospital Bonn (UKB) identified a potentially innovative therapeutic approach for people with cisplatin-resistant in testicular cancer. The researchers discovered the NAE1 gene as the key regulator of cisplatin resistance in testicular cancer cells using CRISPR gene scissors.

The NAE1 inhibitor MLN4924 not only restored cisplatin's efficacy but also increased tumor cell killing. These findings raise the potential of new and more effective medicines to address cisplatin resistance in patients with testicular cancer, potentially enhancing treatment outcomes. Thus, owing to the advancements in treatment option for testicular cancer is expected to drive the market over the foreseeable future.

The Side Effects Associated For Testicular Cancer Treatment Will Hamper the Growth of the Market

The testicular cancer market is expected to be hamper owing to the factors such as side effects from cancer drugs and lack of early detection. While chemotherapy is effective, it can cause fatigue, nausea, vomiting, numbness, tingling, hearing loss, and ringing in the ears, as well as an increased risk of serious infections.

For instance, the drug bleomycin has been associated to cause serious lung inflammation, prompting immediate notification of symptoms to healthcare providers. Furthermore, people getting treatment for testicular cancer are prone to develop blood clots.

Segment Analysis

The global testicular cancer market is segmented based on types, stages, drug class, treatment, distribution channel, and region.

Owing to its Better Effectiveness, the Surgery Segment Accounted for Approximately 34.6% of the Testicular Cancer Market Share

The surgery segment is poised to dominate the testicular cancer market as it remains a first-line and preferred medical treatment for testicular cancer owing to its effectiveness, advancements in technologies, and better cure for testicular cancer. Surgery is the mainstay treatment for this cancer that involves the removal of lymph nodes in the area behind the abdomen lining called the retroperitoneum.

Also, radical inguinal orchiectomy surgery is performed to treat both seminoma and non-seminoma testicular cancers. Furthermore, advancement in technologies such as minimally invasive procedures is driving market growth.

For instance, Mount Sinai Hospital performed robot-assisted retroperitoneal lymph node dissection (R-RPLND) surgery. R-RPLND is a new surgical treatment for testicular cancer that is less invasive than open RPLND. The surgery involves making five small incisions to resect tumors in the retroperitoneum, which allows patients to recover faster. Thus, owing to the advancement in surgery treatment the segment is expected to dominate over the forecast period.

Geographical Penetration

North America Accounted for Approximately 40.7% of the Market Share in 2022, Owing to the Increase in the Number of Clinical Trails

North America, particularly the United States, dominates the global testicular cancer market due to its presence of established market players, along with increasing funding by the companies for the development of novel treatment approaches. Furthermore, the increasing number of clinical trials led to novel treatments for better patient outcomes.

For instance, UNC Lineberger Comprehensive Cancer Center in collaboration with University Cancer Research Fund at Lineberger Comprehensive Cancer Center is conducting a clinical trial began in 2022. This is a phase 2 clinical trial for adults with Nonseminomatous Germ Cell Tumours (NSGCT). The objective of this research is to establish a repository and look for the presence of changed T cells in the subjects' plasma or tumors. The biospecimens collected, which include tumor tissue, blood, and modified T cells, will be utilized to learn more about the existence and longevity of modified T cells in the body and tumor.

Furthermore, the study attempts to boost future cancer treatment choices by merging two separate ways of fighting disease: antibodies and T cells. The study is based on the safety and efficacy data from prior ATLCAR dosing trials. CD30 is a treatment that combines autologous T lymphocyte chimeric antigen receptor cells that are specific for the CD30 antigen with patients and the estimated completion of a trial is in December 2026.

Competitive Landscape

The major global players in the testicular cancer market include Pfizer Inc., Fresenius Kabi AG, Abbott, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Xediton Pharmaceuticals, Accord Healthcare Limited, Baxter Healthcare Corporation, Sandoz International GmbH and Hikma Pharmaceuticals PLC. among others.

COVID-19 Impact Analysis

The COVID-19 pandemic can have an impact on the testicular cancer market, particularly in the context of male reproductive health. Because males are more susceptible to COVID-19, researchers have looked into whether the virus impacts testicular function and whether it is present in seminal fluid. Following COVID-19 infection, studies have shown changes in semen parameters, alterations in the hormonal axis, and gamete dysfunction.

The identification of viral proteins in testicular tissue after death adds support to the possibility of testicular COVID-related harm. Furthermore, infection with SARS-CoV-2 could affect pro-inflammatory mediators, potentially causing testicular injury and raising the risk of infertility. These findings indicate the importance of more research on the long-term effects of COVID-19 on male reproductive health and its potential impact on the testicular cancer market.

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is having impact on the global testicular cancer market. The conflict has decreased access to healthcare services in Ukraine, making it harder for testicular cancer patients to receive critical treatment. The increased financial load on patients as a result of treatment costs and economic instability has further hampered access to care. Delayed diagnosis and treatment have also been noted as people are unwilling to seek medical help during the conflict.

These obstacles have had a detrimental impact on the worldwide testicular cancer market, producing slower growth than expected. However, there is potential for development, such as a greater emphasis on creating more effective treatment options and improving testicular cancer awareness in Ukraine. As the war ends and healthcare access improves, the market is projected to rebound. Nonetheless, the conflict's impact on the market is still enormous, necessitating continual efforts to handle the problems and opportunities it brings.

By Types
• Germ Cell Tumors
Seminomas
• Classical Seminoma
• Spermatocytic Seminoma
Non-Seminomas
• Embryonal Carcinoma
• Yolk Sac Carcinoma
• Choriocarcinoma
• Teratoma
• Stromal Tumors
Leydig Cell Tumors
Sertoli Cell Tumors
• Others

By Stages
• Stage 0
• Stage I
• Stage II
• Stage III

By Drug Class
• Alkylating Agent
• Topoisomerase II Inhibitor
• Glycopeptide Antibiotics
• Antimicrotubular Agents
• Others

By Treatment
• Surgery
• Radiation Therapy
• Chemotherapy
• Others

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• On June 23, 2022, BioNTech SE stated that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) classification to BioNTech's fully owned product candidate BNT211 for the third- or later-line treatment of testicular germ cell tumors. BNT211 is a potential first-in-class therapeutic approach that combines two of the Company's proprietary drug products, an autologous chimeric antigen receptor (CAR) T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac).
• On June 2, 2023, the US Food and Drug Administration is collaborating with Chinese pharmaceutical company Qilu Pharmaceutical to increase supplies of the cancer medicine cisplatin, which is currently in low supply. Apotex, a Canadian pharmaceutical company, will temporarily provide the injectable drug in 50-milligram vials. Cisplatin has a cure rate of more than 90% when used to treat testicular cancer. It also treats malignancies of the bladder, cervix, ovary, lung, stomach, breast, and head and neck.

Why Purchase the Report?
• To visualize the global testicular cancer market segmentation based on type, stages, drug class, treatment, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of testicular cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global testicular cancer market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies